亿帆医药(002019) - 2023 Q1 - 季度财报

Financial Performance - The net profit attributable to shareholders decreased by 21.93% after excluding non-recurring gains and losses[16] - Net profit attributable to shareholders of the listed company decreased by 46.59% to ¥64,774,428.20 from ¥121,266,909.58 year-on-year[38] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥59,978,038.28, down 21.93% from ¥76,821,416.28 in the previous year[38] - Basic and diluted earnings per share both decreased by 50.00% to ¥0.05 from ¥0.10 year-on-year[38] Revenue and Cash Flow - The total operating revenue for Q1 2023 was ¥938,532,039.13, representing a 3.60% increase compared to ¥905,920,591.79 in the same period last year[38] - The net cash flow from operating activities increased by 104.44% compared to the same period last year, mainly due to an increase in received payments[16] - The net cash flow generated from operating activities improved significantly to ¥2,042,875.34, compared to a negative cash flow of ¥46,018,343.12 in the same period last year, marking a 104.44% increase[38] - The company reported cash inflows from operating activities of CNY 1,077,790,038.41 in Q1 2023, an increase from CNY 1,007,886,294.93 in the same period last year, representing a growth of approximately 6.9%[58] - The company reported a decrease in cash outflows for operating activities, totaling CNY 1,075,747,163.07 in Q1 2023, compared to CNY 1,053,904,638.05 in Q1 2022, showing improved cash management[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,588,862,242.31, a slight increase of 0.36% from ¥12,543,503,416.06 at the end of the previous year[38] - The total current assets increased, with cash and cash equivalents reaching ¥1,214,966,438.53, up from ¥1,143,783,700.15[30] - The total liabilities increased to ¥3,423,082,919.34 from ¥3,397,259,755.63 year-on-year[38] - The company's financial assets decreased by 84.29% to 15,000,000.00 yuan, attributed to the redemption of financial products[40] Expenses and Impairments - Tax and additional charges increased by 54.14% to ¥10,831,847.60, primarily due to VAT and related taxes from inter-company transactions[8] - Other income decreased by 89.32% to ¥4,844,318.49, mainly due to a reduction in government subsidies received[8] - Operating costs rose to ¥480,751,477.19, compared to ¥427,472,846.50 in the same period last year[38] - The company recorded an asset impairment loss increase of 814.24% to ¥-1,221,138.65, mainly due to inventory impairment[19] - The company reported a significant reduction in credit impairment losses by 96.74% to ¥-124,882.34, attributed to the recovery of accounts receivable[8] Investments and Development - Investment income improved by 32.17%, with losses from joint ventures decreasing[8] - Research and development expenses for the period were ¥47,510,975.21, up from ¥38,302,629.24 in the previous year[33] - The company received several drug registration certificates, including for the injection of Sulfate Vincristine and other products, enhancing its product portfolio[25][28] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received a drug registration certificate for Lacosamide injection on March 10, 2023[48] - The company’s subsidiary, Yiyi Biopharmaceutical Development (Shanghai) Co., Ltd., received a clinical trial approval notice for the product F-652 on March 21, 2023[50] Financing Activities - Total cash inflow from financing activities was $1,112,952,122.70, compared to $814,866,505.67 in the prior period, reflecting a significant increase[78] - Cash outflow from financing activities amounted to $990,189,051.81, up from $460,883,663.95 in the previous year[78] - Net cash flow from financing activities was $122,763,070.89, a decrease from $353,982,841.72 year-over-year[78] - Cash received from borrowings was $1,112,216,128.41, an increase from $814,866,505.67 in the prior year[78] - Cash paid for debt repayment was $956,496,784.74, significantly higher than $436,316,371.62 in the previous period[78]